Literature DB >> 20428759

Gene expression profiling predicts response to temozolomide in malignant gliomas.

Atsuo Yoshino1, Akiyoshi Ogino, Kazunari Yachi, Takashi Ohta, Takao Fukushima, Takao Watanabe, Yoichi Katayama, Yutaka Okamoto, Norio Naruse, Emiko Sano, Kouhei Tsumoto.   

Abstract

Malignant gliomas are highly lethal neoplasms that cannot be cured with currently available therapies. Temozolomide (TMZ) is a recently introduced alkylating agent that has yielded significant benefits and become a key agent in the treatment of high-grade gliomas. However, its survival benefit remains unsatisfactory. Understanding the molecular basis of TMZ sensitivity/resistance is necessary for improving the treatment outcome by devising strategies that are able to circumvent primary drug resistance. We therefore combined the in vitro TMZ response with microarray gene expression data to identify genes that could potentially be used to predict the response of malignant gliomas to TMZ therapy. We first obtained the individual IC50 values for TMZ in seven malignant glioma cell lines (A-172, AM-38, T98G, U-87MG, U-138MG, U-251MG and YH-13) and then identified the genes whose expression correlated most highly with TMZ sensitivity employing a cDNA microarray. We present here a list of the most highly up-regulated and down-regulated genes which may be involved in conferring TMZ sensitivity/resistance in malignant gliomas, although most of the genes have not been implicated as a causal factor in the TMZ response except MGMT. We also demonstrated and confirmed the MGMT methylation status, quantitative MGMT mRNA levels, and MGMT protein expression levels in TMZ resistant glioma cells in vitro. Our results are thus consistent with previous studies and suggest that a dominant mechanism conferring sensitivity/resistance to TMZ exists in malignant glioma cells. Although the present study dose have several limitations, our reported candidate genes could represent not only potential molecular markers for TMZ sensitivity/resistance but also chemotherapy targets. Furthermore, the present study could provide a foundation for alternative therapeutic strategies including novel combination treatments that incorporate additional reagents directed at overcoming resistance to TMZ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428759     DOI: 10.3892/ijo_00000621

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  34 in total

1.  Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.

Authors:  Tsutomu Nakazawa; Mitsutoshi Nakamura; Ryosuke Matsuda; Fumihiko Nishimura; Young Soo Park; Yasushi Motoyama; Yasuo Hironaka; Ichiro Nakagawa; Hiroshi Yokota; Shuichi Yamada; Kentaro Tamura; Yasuhiro Takeshima; Kouji Omoto; Yoshitaka Tanaka; Yukiteru Ouji; Masahide Yoshikawa; Takahiro Tsujimura; Hiroyuki Nakase
Journal:  J Neurooncol       Date:  2016-07-08       Impact factor: 4.130

2.  Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.

Authors:  Jennifer E Adair; Brian C Beard; Grant D Trobridge; Tobias Neff; Jason K Rockhill; Daniel L Silbergeld; Maciej M Mrugala; Hans-Peter Kiem
Journal:  Sci Transl Med       Date:  2012-05-09       Impact factor: 17.956

3.  Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Authors:  Mengxian Zhang; Tobias W Herion; Carmen Timke; Na Han; Kai Hauser; Klaus J Weber; Peter Peschke; Ute Wirkner; Michael Lahn; Peter E Huber
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

4.  Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression.

Authors:  Gulcin Tezcan; Berrin Tunca; Ahmet Bekar; Ferah Budak; Saliha Sahin; Gulsah Cecener; Unal Egeli; Mevlut Ozgur Taskapılıoglu; Hasan Kocaeli; Sahsine Tolunay; Hulusi Malyer; Cevdet Demir; Gulendam Tumen
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

5.  Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.

Authors:  Yi Cui; Asia Naz; David H Thompson; Joseph Irudayaraj
Journal:  Mol Pharm       Date:  2015-03-18       Impact factor: 4.939

6.  Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.

Authors:  S G Creemers; P M van Koetsveld; E S R van den Dungen; E Korpershoek; F J van Kemenade; G J H Franssen; W W de Herder; R A Feelders; L J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2016-09-07       Impact factor: 5.958

7.  Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.

Authors:  Ashok Kumar Sharma; Lokesh Gupta; Hitesh Sahu; Arem Qayum; Shashank K Singh; Kartik T Nakhate; Umesh Gupta
Journal:  Pharm Res       Date:  2018-01-02       Impact factor: 4.200

8.  Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.

Authors:  Gulcin Tezcan; Berrin Tunca; Ahmet Bekar; Murat Yalcin; Saliha Sahin; Ferah Budak; Gulsah Cecener; Unal Egeli; Cevdet Demir; Gokcen Guvenc; Gozde Yilmaz; Leman Gizem Erkan; Hulusi Malyer; Mevlut Ozgur Taskapilioglu; Turkkan Evrensel; Ayhan Bilir
Journal:  Cell Mol Neurobiol       Date:  2014-09-12       Impact factor: 5.046

9.  Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells.

Authors:  Raffaela Silvestre Ignarro; Gustavo Facchini; André Schwambach Vieira; Daniela Rodrigues De Melo; Iscia Lopes-Cendes; Roger Frigério Castilho; Fabio Rogerio
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

10.  Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways.

Authors:  Gustavo Facchini; Raffaela Silvestre Ignarro; Erika Rodrigues-Silva; André Schwambach Vieira; Iscia Lopes-Cendes; Roger Frigério Castilho; Fabio Rogerio
Journal:  J Neurooncol       Date:  2017-11-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.